Targeting endothelial dysfunction with carvedilol improves intradialytic and interdialytic blood pressure and reduces the frequency of intradialytic hypertension in patients on hemodialysis, according to new findings. In a prospective, 12-week study of 25 hemodialysis patients with intradialytic hypertension, Inrig and colleagues found that carvedilol improved flow-mediated vasodilation. Predialysis systolic blood pressure was unchanged by treatment but postdialysis systolic blood pressure and frequency of intradialytic hypertension were reduced.